drugset

drugset / Trial / NCT03983031

Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

NCT03983031 ↗

Phase 1 Completed 11 enrolled Region Örebro County Örebro University, Sweden · collab

NaSingle-groupSingle-blindTreatment

Summary

This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.

Timeline

Start: 2019-08-08
Primary completion: 2022-03-31
Completion: 2022-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	1000 mg	Other

Indications